Hefei, January 28 news (reporter Xu Qiuyun) On the afternoon of January 27, the Department of Neurology of the High-tech Branch of the First Affiliated Hospital of Anhui Medical University successfully conducted intrathecal injection treatment of Nocinasin sodium injection for 2 adult patients with spinal muscular atrophy (SMA) type III. This is the first batch of adult patients in Anhui who benefited after the drug was officially included in the implementation of medical insurance.
"Every small group should not be abandoned." On December 3, 2021, the National Medical Insurance Bureau announced the results of the adjustment of the 2021 medical insurance drug list, a total of 74 new drugs were added to the list, which was implemented on January 1, 2022. Known as the "sky-high life-saving drug", The sodium injection of Northinasin has been reduced from 700,000 yuan / needle to 33,000 yuan / needle through the "soul bargain" of the National Medical Insurance Bureau, bringing hope to patients with spinal muscular atrophy (SMA).
The Central Broadcasting Network issued a picture of the First Affiliated Hospital of An medical university
Mr. Yan of Bengbu is 35 years old and works in school; Mr. Xu, 30, lives in Hefei and is an IT practitioner. Both are genetically diagnosed SMA patients, limb weakness, walking posture is different from ordinary people, and climbing stairs is also very difficult. It has been 6 years since the diagnosis was confirmed, but the drug has not been treated for economic reasons. In late January, the two were admitted to the Department of Neurology of the High-tech Branch of the First Affiliated Hospital of Anyi University. Combined with the patient's specific condition, the medical staff formulated a sound and reasonable individualized assessment and drug delivery plan, straightened out the dual-channel drug purchase route of the drug, and on January 27, Mr. Yan and Mr. Xu successfully received intrathecal injection treatment of Northinalsan sodium.
Currently, the two patients are in good condition and have been discharged from hospital on 28 January, with plans to receive a second injection a few years later.
Nosinacin sodium injection is only 5 ml. Since the drug requires special transport equipment for constant temperature transport, the pharmacist accompanies the entire sheath injection process. According to the instructions for use of the drug, the drug needs to be injected intrathecally, that is, the drug is injected directly into the subarachnoid cavity through lumbar puncture, so that the drug is dispersed in the cerebrospinal fluid and directly acts on nerve cells. According to Chen Xianwen, chief physician of the Department of Neurology of the High-tech Branch of the First Affiliated Hospital of Anyi University, during the puncture, the puncture is generally performed between the L3 and L4 segments of the lumbar spine, and 5 ml of cerebrospinal fluid is first extracted. Then, take the drug from the incubator, put it in your hand and heat it to thaw it to room temperature; then inject 5 ml of the drug in a few minutes, extremely slowly.
SMA is a rare inherited neuromuscular disorder caused by deletion or mutation of the survival motor neuron 1 (SMN1) gene. The disease is characterized by the loss of motor neurons in the spinal cord and lower brainstem, leading to severe, progressive muscle atrophy and weakness. Eventually, people with SMA may lose the ability to walk and have difficulty completing basic life functions such as breathing and swallowing, leading to reduced quality of life and life expectancy, as well as severe care and financial stress for families.
Patients with SMA require lifelong injection of noncinazine sodium therapy, and through subsequent continuous medication, it is expected to stabilize and improve the patient's motor function. The development of adult injections has accumulated valuable experience for active and effective treatment in the future, and paved the way for the treatment of adult SMA in Anhui Province.